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Salvage prostate cryoablation (SCA) for recurrent localized prostate cancer after radiotherapy has been
studied in Western countries for more than a decade. We present our experience of SCA in a Taiwanese
medical center. We performed four cases of SCA for recurrent localized prostate cancer after radio-
therapy. The data recorded included age, cancer stage, prostate-speciﬁc antigen (PSA) level, Gleason
score, prostate volume and patient outcome. The median follow-up period was 17 months. All cases were
biopsy-proven to have residual cancer before cryoablation. After SCA, 25% of the patients reached un-
detectable PSA levels, 50% showed response but did not reach undetectable levels, and 25% showed no
decrease in PSA. The median recurrence-free duration after SCA was 18 months in the patients who
experienced a decrease in PSA. ADT was initiated after SCA for the patient who did not show any
response, and bone metastasis was later diagnosed in that patient. Most patients experienced obstructive
voiding problems after SCA, which improved over time. SCA is a safe salvage option for prostate cancer
patients with local recurrence after RT. The preliminary results are encouraging. More extensive imagery
to exclude extra-glandular disease is warranted before SCA. A longer follow-up period and larger sample
size are necessary to delineate the beneﬁts more conclusively.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Studies have shown that cryoablation may be beneﬁcial as
salvage therapy for local recurrence of prostate cancer after radio-
therapy (RT), despite an increased complication rate.1 Most studies
were conducted in countries with predominantly white and
African-American populations.1 We herein present our preliminary
experience of salvage cryoablation (SCA) for post-RT biochemical
recurrence (BCR) of prostate cancer in this Taiwanese series.2. Methods
From October 2000 to June 2013, 17 cases of cryoablation for
prostate cancer were performed in our institution, of which six
(35%) were salvage cases who had previously received RT with BCR.
Two patients were excluded from this study because they receivedina Medical University Hos-
.
ociation. Published by Elsevier Ta
et al., Salvage prostate cryo
10.1016/j.urols.2015.11.114heterogeneous treatment before undergoing SCA. BCR was deﬁned
using the Phoenix criteria [post-treatment nadir prostate-speciﬁc
antigen (PSA) levels plus 2 ng/mL], instead of the Stuttgart
criteria (nadir plus 1.2 ng/mL).2 Patient demographics and pre-SCA
data are presented in Table 1. The median nadir PSA after RT was
0.37 ng/mL among responders, and the median pre-SCA PSA was
5.47 ng/mL.
After SCA, PSA levels were followed at the outpatient depart-
ment regularly. Voiding function, erectile function, and overall
satisfaction were documented. Before SCA, Patient 4 received
neoadjuvant androgen deprivation therapy (ADT), but BCR was
noted after RT, so ADT was given until 2 years before SCA. All nodes
were negative in the patient who received bilateral pelvic lymph
node dissection. All patients received transrectal ultrasonography-
guided prostate biopsy before SCA, and adenocarcinomawas found
in every patient.
We used four Endocare® Cryocare® cryoprobes (Health-
Tronics™, Inc. Austin, Texas, USA) for glands measuring 10 cm3 or
less (apex  2, base  2) and six cryoprobes for glands measuring
over 10 cm3. In Patient 3, the left neurovascular bundle was sparediwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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Table 1
Patient demographics and pre-SCA treatment information.
Patient Age
(y)
cTN iPSA
(ng/mL)
Gleason
grade
Recurrence
risk
RT dose
(cGy)
Treatment other
than RT
Nadir PSA after RT
(ng/mL)
Time from RT to
BCR (mo)
Time from RT to
Cryo (mo)
Pre-SCA PSA
(ng/mL)
1 80 T2bN0 27 2þ2 High 7560 Nil 0.349 45 47 2.92
2 77 T2aN0 18.5 4þ3 Intermediate 7560 Nil 0.379 37 49 8.02
3 71 T2aN0 20.4 4þ5 High d Nil 1.72 24 40 9.62
4 77 T3bN0 33.9 4þ4 High 8100 ADTa 0.275 68 68 1.52
Median 77 d 26.95 7.5 d d d 0.364 41 48 5.47
ADT ¼ androgen deprivation therapy; BCR ¼ biochemical recurrence; Cryo ¼ cryoablation; cTN ¼ clinical T and N stage; PSA ¼ prostate-speciﬁc antigen; RT ¼ radiotherapy;
SCA ¼ salvage cryoablation.
a Neoadjuvant ADT þ RT þ adjuvant ADT.
Table 2
Salvage cryoablation of prostate-related information.
Patient Prostate
size
(cm3)
No. of
cryoprobes
Hospital
stay (d)
Catheterized
period (d)a
1 10 4 4 17
2 19.3 6 4 11
3 23.8 6 6 10
4 7.49 4 5 15
Median 14.65 5 4.5 13
a Suprapubic catheter.
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pubic catheter was inserted, and double cycles of freezeethaw
were applied. Urethral warming was then maintained for 30 mi-
nutes. A 20-Fr urethral Foley catheter was then inserted. Lower
urinary tract symptoms (LUTSs) were quantiﬁed using the Inter-
national Prostate Symptom Score (IPSS).3 Erectile function was
assessed with the International Index of Erectile Function (IIEF-5)
score.4
3. Results
The detailed results of SCA are shown in Table 2. Median follow-
up period was 17 months, ranging from 10 to 27 months. Unde-
tectable PSA levels after SCA were noted in one patient, whereas
two patients reached a detectable nadir level, and one patient
showed no decrease in PSA. The median recurrence-free duration
after SCA is 18 months in the three patients with response. The
changes in PSA level are shown in Table 3 and Figure 1. Patient 1
exhibited BCR at 21 months after SCA, and computed tomography
scan at 28 months suggested local recurrence over the right urinary
bladder neck and metastasis to the left hypogastric lymph node.
The PSA level of Patient 4 continued to increase after SCA, and
therefore, we initiated ADT 6 months after SCA. His pre-SCA bone
scan suggested trauma of the T8 vertebra; however, the bone scan
done at 5 months post-SCA suggested vertebral metastasis.
All patients had some form of LUTSs before SCA. After SCA,
exacerbation of LUTSs was noted in all patients. The IPSS changes
are presented in Table 4. The ratio of subscore of voiding symptomsTable 3
Changes in PSA level (ng/mL) after SCA.
Patient Pre-SCA PSA 1 mo 2 mo 3 mo 6 mo 9 m
1 2.92 2.25 3.692 2.554 1.595 3.7
2 8.02 0.312 0.02 0.029 0.036 0.0
3 9.62 0.785 <0.008 d <0.008 d
4 1.52 3.683 4.35 5.07 13.86 AD
ADT ¼ androgen deprivation therapy; PSA ¼ prostate-speciﬁc antigen; SCA ¼ salvage cr
a Because of ﬂuctuating PSA, blood tests were done more frequently, and the nadir le
b ADT initiated due to SCA failure.
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derlying bladder outlet obstruction (BOO) related to prostatic
enlargement, and laser photovaporization of the prostate was done
4 years before SCA. For this patient, acute urinary retention (AUR)
was noted 5 months after SCA, and transurethral resection of the
prostate was done in another hospital. After the procedure, he
suffered from mild stress urinary incontinence (SUI), using three
pads/day. Patient 2 was diagnosed with membranous urethral
stricture postoperatively, and therefore transurethral urethrotomy
was performed 9 months after SCA, and at the conclusion of this
study he could void well. Patients 3 and 4 did not have SUI or
urinary retention both before and after SCA.
Only one patient (Patient 3) was sexually active before SCAwith
a reported IIEF score of 21/25, whereas other patients had an IIEF
score of 0e1/25. After SCA, his IIEF score was 0/25 until 1 year post-
SCA, but he was partially responsive to alprostadil intracavernous
penile injections. At 15 months post-SCA, he began to experience
occasional morning erections.4. Discussion
The initial results from the Cryo On-Line Data Registry reported
a 5-year disease-free survival (DFS) of 55%; additionally, Wenske
et al reported a similar 5-year DFS (63%).5,6 In our study, no mor-
tality is seen, but concluding on DFS may be premature due to the
short follow-up duration. In the three patients responsive to SCA
initially, one experienced extraglandular recurrence at 2 years post-
SCA, whereas the other two patients were disease-free. Mouraviev
et al7 listed factors that were predictive of better outcome,
including lower PSA level, Gleason grade, and stage. In our insti-
tution, ADT-naïve patients had a better outcome, which might be
related to a lower initial stage and PSA. Certain cases of SCA failures
might be due to the presence of undetected extraglandular disease
prior to SCA. The patient in our study who did not respond to SCA
actually had bone metastasis, which was not detected until after
SCA.Whole-gland therapy is used for SCA inmost centers.5Wenske
et al,6 however, reported an acceptable outcome in select cases of
focal SCA. In our cases, all cases utilized whole-gland therapy, but
for Patient 3, unilateral sparing of the neurovascular bundle was
done with satisfactory oncological outcome.o 12 mo 15 mo 18 mo 21 mo 24 mo 27 mo
7 1.613a 2.399 1.49 3.568 4.08 8.32
5 0.053 0.09 0.15
<0.008 0.01
Tb
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Figure 1. The graph of serum prostate-speciﬁc antigen levels against time after salvage
cryoablation (derived from Table 3). Cryo ¼ cryoablation.
Table 4
Changes in IPSS after SCA.
Months after SCA Patient 1 Patient 2 Patient 3 Patient 4 Median
0 9 8 10 16 9.5
1 32 16 31 17 24
2 31 11 22 15 18.5
3 d 10 13 25 d
6 d 10 d 16 14a
9 23 d 12 d
IPSS ¼ International Prostate Symptom Score, SCA ¼ salvage cryoablation.
a Median of data from 6e9 months.
Table 5
The ratio of the voiding subscore over storage subscores of IPSS after SCA.
Months after SCA Patient 1 Patient 2 Patient 3 Patient 4 Median
0 1.25 d 0.67 0.8 d
1 1.13 0.89 1.38 0.55 1.01
2 1.21 1.75 1.75 0.36 1.48
3 d 1 0.86 0.79 d
6 d 0.67 d 0.86 0.69a
9 0.64 d 0.71 d
IPSS ¼ International Prostate Symptom Score; SCA ¼ salvage cryoablation.
a Median of data from 6e9 months.
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been a focus for research. Kimura et al8 reported that SCA is a
predictor for poorer postoperational voiding function when
compared with primary cryoablation, whereas pre-SCA severity of
LUTSs and prostate sizewere not signiﬁcantly related. It can be seen
from our study that SCA may lead to de novo LUTSs or exacerbate
pre-existing LUTSs. Wenske et al6 reported that 0.9% of his patients
had severe post-SCA SUI, which required an artiﬁcial sphincter or
transurethral sling. In our study, no patients experienced SUI
directly after SCA, although one patient only experienced SUI after
transurethral incision of bladder neck for AUR.
IPSS is a widely accepted system to quantify male LUTSs.3 LUTS
initially worsened to its maximum in the ﬁrst 2 months post-SCA,
and then gradually improved, albeit not to pre-SCA levels. The ra-
tio of subscore of V/S9 implied that patients had more storage
symptoms before SCA, and then voiding symptoms were dominant
for the ﬁrst 2 months post-SCA, but the ratio gradually reversed.
Tissue necrosis occurs after cryoablation10; therefore, BOO may be
exacerbated before tissue edema subsides. The possibility of erec-
tile dysfunction (ED) after SCA is well-documented.6,7 In our series,
Patient 3 experienced some degree of ED after SCA, which was
responsive to alprostadil. All the other patients were impotent
before SCA.
This series has certain limitations. The patient number was too
small to enable statistical analysis. This is a retrospective series of aPlease cite this article in press as: Siu JJ-Y, et al., Salvage prostate cryo
Urological Science (2015), http://dx.doi.org/10.1016/j.urols.2015.11.114salvage therapy, which may explain why certain patients received
multiple therapies besides RT, and hence the heterogeneous data.
To conclude, SCA may be used safely as a salvage option in
Taiwanese prostate cancer patients with local recurrence after RT.
The preliminary results are encouraging. If BCR is noted after RT,
rebiopsy of the prostate gland is strongly recommended, and SCA
should only be carried out in patients with biopsy-proven residual
disease. More extensive imagery to exclude extraglandular disease
may be warranted before SCA. A longer follow-up period and larger
sample size are necessary to delineate the beneﬁts more
conclusively.Conﬂicts of interest
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